Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Limaye, Sewanti; Kumar, Prashant; Pragya, Ramya; Sambath, Janani; Patil, Darshana; Srinivasan, Ajay; Apurva, Sachin; Srivastava, Navin; Patil, Sanket; Patil, Revati; Datta, Vineet; Akolkar, Dadasaheb; Datar, Rajan

doi:10.18632/oncotarget.28262

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the frequent and often high-level AR expression in many other tumor types, it is obvious to consider AR targeting therapies for these tumors. The successful use of anti-androgen drugs has been reported in various cancer types including carcinomas of the breast [43], salivary gland carcinoma [44,45], ovarian cancer [46], bladder cancer [47], and salivary duct carcinoma [10,48,49]. Clinical trials on the use of anti-androgen drugs in non-prostate cancers are currently underway (according to clinicaltrials.gov, accessed on 28 December 2023) in breast carcinoma (especially triple negative breast cancer) (n = 12), salivary gland carcinoma (n = 6), or bladder cancer (n = 2).…”

Section: Discussionmentioning

confidence: 99%

Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors

Viehweger,

Hoop,

Tinger

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Androgen receptor (AR) is a transcription factor expressed in various normal tissues and is a therapeutic target for prostate and possibly other cancers. A TMA containing 18,234 samples from 141 different tumor types/subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. AR positivity was found in 116 tumor types including 66 tumor types (46.8%) with ≥1 strongly positive tumor. Moderate/strong AR positivity was detected in testicular sex cord-stromal tumors (93.3–100%) and neoplasms of the prostate (79.3–98.7%), breast (25.0–75.5%), other gynecological tumors (0.9–100%), kidney (5.0–44.1%), and urinary bladder (5.4–24.2%). Low AR staining was associated with advanced tumor stage (pTa versus pT2-4; p < 0.0001) in urothelial carcinoma; advanced pT (p < 0.0001), high tumor grade (p < 0.0001), nodal metastasis (p < 0.0001), and reduced survival (p = 0.0024) in invasive breast carcinoma; high pT (p < 0.0001) and grade (p < 0.0001) in clear cell renal cell carcinoma (RCC); and high pT (p = 0.0055) as well as high grade (p < 0.05) in papillary RCC. AR staining was unrelated to histopathological/clinical features in 157 endometrial carcinomas and in 221 ovarian carcinomas. Our data suggest a limited role of AR immunohistochemistry for tumor distinction and a prognostic role in breast and clear cell RCC and highlight tumor entities that might benefit from AR-targeted therapy.

show abstract